Research funder · Australia
Therapeutic Innovation Australia
- Grants since 2016
- 310
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 146
- Funded works, all time
- 282
Grants
2026
Development of a novel anti inflammatory gene therapy for type 1 diabetes
2026
High-throughput drug screening for paediatric epilepsy due to pathogenic variants in CDKL5
2026
High-Throughput Phenotypic and Target-Based Profiling of Novel Antimicrobials Using Imaging and Proteomics
2026
Identification of novel therapies for the treatment of acral lentiginous melanoma
2026
Treating the mitochondria to improve endothelial function of patients with coronary artery disease
2026
Screen for new agents to selectively kill a novel defect in melanomas
2026
Development of a high-throughput phenotypic screen for lysosomal storage disorders
2026
Developing Precision Medicine Therapies for PCDH19-Clustering Epilepsy
2026
Dual-Action mRNA Therapy for RDEB: Restoring Skin Integrity and Reducing Chronic Itch
2026
Development of a high throughput screening platform of patient-derived iPSC motor neuron for enhancers of energy metabolism as a therapeutic intervention in axonal degeneration
2026
Production and Lead Selection of Humanised Anti-Glypican-1 Antibodies
2026
Caspase-1 inhibitors for the treatment of inflammatory disease
2026
Development of Novel Gut-Targeted Antibiotics for the Treatment of Multidrug-Resistant Pathogens
2026
Self-amplifying RNAs with modified NTPs: a next-generation vaccine and therapeutic platform.
2026
Utilising high-throughput drug screening for mitochondrial metabolite repair disorders
2026
Screening chemically diverse compounds that represent untested chemical space for activity against Plasmodium malaria parasites
2026
Toxicology and pharmacokinetic profiling of a stem cell mobilisation agent
2026
Developing immunotherapies to enhance CD8 T-cell-mediated clearance of HIV-1-infected cells
2026
Production of a HER2 binding nanobody for the assembly of targeted novel dendrimer therapeutics for breast and gastric cancer
2026
Development of SRPK1 kinase inhibitors for osteoarthritis pain
2026
Novel Eph Receptor Antibody Drug Conjugate Therapy Development for the Treatment of Paediatric Brain Cancer
2026
Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease
2026
Neuroprotective efficacy of poly-argine-18 (R18) in a relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) mouse model of multiple sclerosis (MS)
2026
Developing the next generation of cancer mRNA therapeutics
2026
Developing next generation cardio-regenerative therapeutics to treat systolic heart failure
2026
Long-term AAV-mediated genetic rescue of photoreceptors in retinitis pigmentosa
2026
Bioconjugation and characterisation of novel Antibody-Drug Conjugates for in vivo (mouse) studies targeting breast cancer
2026
Validation of GMP-compliant manufacture of corneal endothelial cells for injection
2026
Muscle-targeted adeno-associated viruses for safer gene therapy
2026
A Programmable RNA Therapy Platform to Treat Liver Cancer
2026
Developing Precision Covalent Therapeutics to Target Protein Disulfide Isomerase A6: A Novel and Safer Strategy Against Acute Ischaemic Stroke
2026
Novel Small Molecule G9a Inhibitors for Treating Colon and Liver Cancers
2026
Developing a GMP Compliant Adipose Derived Stem Cell Manufacturing Process for Cartilage Based Stem Cell Therapies
2026
Autologous haematopoietic stem cells, moving transplantation into the 21st century
2026
Process development for the preparation and delivery of induced pluripotent stem cell derived cardiomyocytes for end stage heart failure.
2026
Development of anti-viral agents targeting severe viral infections
2026
Development of novel agents targeting severe viral infections
2026
De Novo Antibody Generation Against Glycosylated Cancer Antigens for Next-Generation Immunotherapies
2026
Advanced gene therapy optimisation for ALS and FTD
2026